Applied DNA Sciences

Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference

Retrieved on: 
Thursday, February 9, 2023
Conference, Applied DNA Sciences, Webcast, Therapy, Event, Pharmaceutical industry, Broadcasting

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present virtually at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 2:20 p.m.

Key Points: 
  • NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present virtually at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 2:20 p.m.
  • ET.
  • Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com.
  • A replay will also be available following the webcast.

Applied DNA Announces Publication of Peer-Reviewed Journal Article Validating Potential Use of linearDNA™ as a New Class of DNA-Based Vaccines

Retrieved on: 
Thursday, January 5, 2023
Veterinary, Research, Infectious Diseases, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, LNP Media Group, BioRxiv, RNA transfection, Cornell University College of Veterinary Medicine, Applied Biosystems, DNA, Polymerase chain reaction, Dog, CDMO, CAR, Severe acute respiratory syndrome coronavirus 2, Veterinary medicine, Safety, Therapy, Applied DNA Sciences, Manuscript, Vaccine, PCR, LNP

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development .
  • An initial manuscript detailing the study’s findings was published in preprint form on bioRxiv in July 2022.
  • The study demonstrated safety and immunogenicity of a linearDNA vaccine candidate against SARS-CoV-2 in a cohort of family-owned felines.
  • Prime-boost vaccinations were administered by electro-gene-transfer intramuscularly to the cohort, which induced robust neutralizing antibody titers and cellular immune responses.

Applied DNA Announces Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Wednesday, December 14, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Biotechnology, Therapy, Textile, Exercise, CDMO, Operating cost, Calendar, Q&A, Sale, DNA, Uyghur Forced Labor Prevention Act, IVT, Research, PCR, Applied DNA Sciences, Policy, Investment, MDX, COVID-19, RNA transfection, Growth, CGMP, Insurance, Fine chemical, Pharmaceutical industry, Security (finance)

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced consolidated financial results for the fourth quarter and fiscal year ended September 30, 2022.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced consolidated financial results for the fourth quarter and fiscal year ended September 30, 2022.
  • Gross profit was $417 thousand, or 12%, compared to $992 thousand, or 33%, in the prior fiscal year period.
  • Excluding non-cash expenses, Adjusted EBITDA was negative $3.4 million compared to negative $3.3 million in the prior fiscal year period.
  • The Company will hold a conference call and webcast to discuss its fourth quarter and fiscal year 2022 financial results on Wednesday, December 14, 2022, at 4:30 PM ET.

Applied DNA to Report Fiscal 2022 Fourth Quarter and Year End Financial Results on December 14, 2022

Retrieved on: 
Monday, December 12, 2022
Research, Genetics, Stem Cells, Biotechnology, Other Health, Health, General Health, Other Science, Science, PCR, Biotechnology, Applied DNA Sciences, Polymerase chain reaction, Applied Biosystems, DNA, Vaccine

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022.
  • The Companys management will host a conference call with investors and covering analysts starting at 4:30 pm ET that same day.
  • Participants should ask to be connected to the Applied DNA Financial Results conference call.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA").

Applied DNA to Establish North America’s First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York

Retrieved on: 
Monday, October 24, 2022
Other Manufacturing, Research, Genetics, Clinical Trials, Stem Cells, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Adoption, LinkedIn, Drug Quality and Security Act, RNA transfection, Medicine, SEC, Therapy, Contract research organization, Growth, CGMP, Cell, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Biotechnology, United States Department of Agriculture, Research, Twitter, RNA, Securities Act of 1933, Polymerase chain reaction, History, PCR, Private Securities Litigation Reform Act, Food, Goal, Good laboratory practice, Company, Industry, Health, CEO, Securities Exchange Act of 1934, Forward-looking statement, DNA, USDA, Calendar, FDA, United States Department of State, CRO, Leadership, Fine chemical, Vaccine, Medical device, Applied DNA Sciences

Steve Bellone, the Suffolk County Executive, stated, Long Islands DNA Corridor is the beating heart of the regions premier life sciences hub.

Key Points: 
  • Steve Bellone, the Suffolk County Executive, stated, Long Islands DNA Corridor is the beating heart of the regions premier life sciences hub.
  • The area continues to advance the forefront of modern medicine with local talent like Applied DNA, whose enzymatically produced DNA holds the potential to transform human health.
  • I am pleased to lend my Offices support to help it reach its goals for the benefit of us all.
  • Unlike large and capital-intensive plasmid-based DNA production facilities, the LinearDNA platform uses bench-top equipment to rapidly produce DNA in a minimal physical footprint.

Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA™ To-Date

Retrieved on: 
Monday, October 10, 2022
Health, Stem Cells, Genetics, Research, Science, Pharmaceutical, Biotechnology, NYSDOH, Lists of diseases, LinkedIn, Drug Quality and Security Act, SEC, New York State Department of Health, Diagnosis, Annual report, NASDAQ, Biotechnology, RNA, Twitter, Research, Applied DNA Sciences, IVT, Securities Act of 1933, History, PCR, Private Securities Litigation Reform Act, Infection, Company, Cancer, Industry, CEO, Securities Exchange Act of 1934, Bacteria, Forward-looking statement, DNA, FDA, Vaccine, Applied Food Technologies

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA valued above the mid-six-figures.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA valued above the mid-six-figures.
  • LinearDNA is produced using an enzymatic (cell-free) manufacturing platform that eliminates the use of fermenters and bacteria required by plasmid DNA, the industrys current manufacturing standard for DNA.
  • LinearDNA eliminates many of the challenges associated with current plasmid-based DNA manufacturing and produces a DNA product without the risks of bacterial contamination and non-target DNA sequences.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).

Applied DNA and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications

Retrieved on: 
Thursday, September 8, 2022
Veterinary, Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, University, Health, Science, Education, United States Department of State, Partnership, COVID-19, CEO, Securities Exchange Act of 1934, Securities Act of 1933, Veterinary medicine, Research, Applied DNA Sciences, Polymerase chain reaction, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Associate, Medicine, Mouse, Infection, United States Department of Agriculture, Drug Quality and Security Act, USDA, Food, Agreement, LinkedIn, DNA, SEC, Cornell University College of Veterinary Medicine, PCR, Company, FDA, Biotechnology, History, Twitter, Clinical trial, Annual report, Private Securities Litigation Reform Act, Drug development, Health, Forward-looking statement, Vaccine, Applied Food Technologies, LNP, Virology

Recently , Applied DNA announced the successful administration and expression of a lipid nanoparticle-encapsulated (LNP) LinearDNA construct in mice via routine intramuscular (IM) injection.

Key Points: 
  • Recently , Applied DNA announced the successful administration and expression of a lipid nanoparticle-encapsulated (LNP) LinearDNA construct in mice via routine intramuscular (IM) injection.
  • Veterinary DNA vaccines present an attractive opportunity for us, and these animal studies should generate additional key validation data for our platform relevant to veterinary health.
  • Dr. Diel said, Vaccinology research and clinical trials are crucial to developing new prevention strategies that could have transformative applications in animal health.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).

Applied DNA to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022

Retrieved on: 
Wednesday, September 7, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Applied DNA Sciences, NASDAQ, Mark (given name), Board, LinkedIn, DNA, PCR, Conference, Biotechnology, Twitter, Lotte New York Palace Hotel, Director

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time.
  • The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.
  • To listen to a livestream of the Companys presentation, please click on the following link to register for the conference: Applied DNA presentation at the H.C. Wainwright 24th Annual Global Investment Conference
    Location: In-person at the Lotte New York Palace Hotel, New York, NY.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).

Applied DNA Launches Monkeypox Testing Service

Retrieved on: 
Tuesday, September 6, 2022
Managed Care, Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Genetics, Science, Biotechnology, Medical Supplies, Practice Management, Health, Other Science, COVID-19, CEO, Securities Exchange Act of 1934, Securities Act of 1933, Research, Applied DNA Sciences, Monkeypox virus, CLEP, NASDAQ, Laboratory developed test, New York State Department of Health, LinkedIn, DNA, SEC, Infection, PCR, Monkeypox, LDT, FDA, Biotechnology, History, Attention, Certification, LLC, Twitter, NYSDOH, Annual report, Private Securities Litigation Reform Act, TAT, CDC, Forward-looking statement, Vaccine, Applied Food Technologies

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.
  • Having built ADCLs stellar reputation for high-capacity, PCR-based COVID-19 testing with rapid TAT, we believe we can bring to bear the same expertise to the monkeypox public health emergency, stated Dr. James A. Hayward, president and CEO of Applied DNA Sciences.
  • ADCLs monkeypox test utilizes an A17L gene-target specific to monkeypox virus Clade II that enables the qualitative detection and differentiation of the monkeypox virus from other non-variola orthopoxviruses using real-time PCR.
  • To learn more about ADCLs monkeypox testing service, click to: adnas.com/monkeypox-testing
    Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (DNA).

Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval to New York State Department of Health

Retrieved on: 
Friday, August 19, 2022
Research, Medical Supplies, Infectious Diseases, Biometrics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, COVID-19, CEO, Securities Exchange Act of 1934, Securities Act of 1933, Research, Applied DNA Sciences, Monkeypox virus, NASDAQ, Infection, New York State Department of Health, Drug Quality and Security Act, LinkedIn, DNA, SEC, PCR, COVID-19 testing, New Yorkers, LDT, FDA, Biotechnology, Population, History, Twitter, LLC, NYSDOH, Annual report, Private Securities Litigation Reform Act, Forward-looking statement, Vaccine, Applied Food Technologies

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC ("ADCL"), has submitted to the New York State Department of Health (NYSDOH) a validation package for its Company-developed monkeypox virus test in support of a request for full approval as a form of NYSDOH Laboratory Developed Test (LDT).

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC ("ADCL"), has submitted to the New York State Department of Health (NYSDOH) a validation package for its Company-developed monkeypox virus test in support of a request for full approval as a form of NYSDOH Laboratory Developed Test (LDT).
  • The PCR-based diagnostic is designed to identify the genetic signature of the Clade II variant of the monkeypox virus that is currently prevalent in the U.S.
  • Named the Linea Monkeypox Virus 1.0 Assay, the test would be ADCL's second successful LDT in less than one year if approved by the NYSDOH.
  • Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA").